A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

About the study

The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Have type 1 diabetes and on insulin treatment for at least one year prior to screening
Have an HbA1c value of 7.0% to 10.5% inclusive, at screening
Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening
Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study

EXCLUSION CRITERIA

Exclusion Criteria:

Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization.
Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.
Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
Have had chronic or acute pancreatitis
Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening